subscribe
 

Galen acquires Synera® (lidocaine 70mg/tetracaine 70mg) topical patch

Galen, a Northern Ireland based pharmaceutical company, has acquired Synera® (lidocaine 70mg/tetracaine 70mg) topical patch from ZARS Pharma Inc., a wholly owned subsidiary of Nuvo Research Inc.

The Scientist Best Place to Work

Wyatt Technology Corporation, the world leader in absolute macromolecular characterization instrumentation and software, announces it has been ranked among The Scientist magazine’s Best Places to Work in Industry, for the fifth...

Roche halts investigation of aleglitazar

Roche has announced that following the results of a regular safety review of the aleglitazar AleCardio phase III trial, the independent Data and Safety Monitoring Board (DSMB) has recommended to halt the trial due to safety signals and lack...

Scientists develop ground-breaking new method of ‘starving’ cancer cells

A University of Southampton Professor, in collaboration with colleagues at the BC Cancer Agency Research Centre, have discovered a novel way...

Staphylococcus aureus vaccine

A consortium comprising Imaxio, the Jenner Institute at Oxford University, the European Vaccine Initiative and Preclin Biosystems has been awarded a major FP7 grant to support development and phase I clinical trial of an S. aureus vaccine.

3D spheroid assays for cancer drug screening

AMSBIO has introduced a new range of 96-well format 3D Spheroid Cell Proliferation / Viability Assays, providing a new tool to allow...

Antibiotics may increase eczema risk in children, study reveals

Use of antibiotics in early life may increase the risk of developing eczema by up to 40 per cent, according to a new study involving researchers from The University of Nottingham, in the British Journal of Dermatology.

New 10-Plate petri dish racks and coloured tags

Don Whitley Scientific Limited (DWS) has this week launched a new 10-Plate Petri Dish Rack made from stainless steel.

Join Lonza’s free webinar on convenient and efficient non-viral iPSC generation

The first webinar is scheduled for 18 June 2013 at 10 AM CEST (Berlin). The second session will be held on 19 June 2013 at 2 PM EDT (New York).

Cobra Biologics and Novolytics unveil successful development of bacteriophages against bacterial infection

Cobra Biologics and Novolytics have announced a breakthrough in the development of two Staphylococcus aureus based phage products for Phase I clinical trials with a 100 fold increase in upstream process yields.

Roche's RoACTEMRA approved in EU to treat children with rare form of arthritis

Roche has announced that the European Medicines Agency has approved RoACTEMRA to treat children with polyarticular juvenile idiopathic arthritis (PJIA), a rare, chronic and debilitating form of childhood arthritis.

New 2-3 day patient-applied product for sun-damaged skin that can lead to skin cancer

A new treatment for sun-damaged skin that can lead to skin cancer is launched by LEO Pharma

Curie-Cancer and Biolog-id sign partnership agreement

Within the partnership, Curie-Cancer and Biolog-id will develop a pilot system of RFID tags suitable for use in tracking cancer chemotherapy preparations

Sub-Visible Particles: impact on therapeutic proteins

SP Scientific has announced a new LyoLearn webinar, due to run on 27th June 2013, entitled 'Sub-visible Particles: Impacts on Aggregation...

£250k prize offered to encourage human toxicology breakthrough

A £250k prize is being offered to encourage researchers to deliver a breakthrough in toxicology research that could ultimately lead to the...

Roche presents new, fully automated lab solution at Europe’s largest diagnostics conference

System improves efficiency and speed of blood sample testing in medical labs

Auxogyn selected to present at European BioEquity Conference in Stockholm

BioEquity is the top European event for life science investors showcasing companies on the forefront of innovation.

Queen’s scientists develop ‘magic bullet’ nanomedicine for Acute Lung Injury

Researchers at Queen’s University Belfast have devised a ‘magic bullet’ nanomedicine which could become the first effective treatment for Acute Lung Injury or ALI, a condition affecting 20 per cent of all patients in intensive care.

Novartis drug Ilaris® approved by FDA

Novartis announced that the US Food and Drug Administration (FDA) has approved Ilaris® (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis (SJIA) in patients aged 2 years and older.

New nanoparticles research

A Wayne State University researcher has successfully tested a technique that can lead to more effective use of nanoparticles as a drug delivery system.

Pages

Newsbrief

Twitter Icon © Setform Limited
subscribe